The House Energy & Commerce Committee this week continues to clear the decks on drug-pricing legislation that is easiest to attain while two factions -- the House speaker and the White House on one side, and Senate Finance Democrats and Republicans on the other -- work separately on larger, more politically divisive reforms. Meanwhile, the administration last week backed down from its plan to use protected drug classes as a tool to control prices, and that move is in turn...